APASL consensus statements and recommendation on treatment of hepatitis C
M Omata, T Kanda, L Wei, ML Yu, WL Chuang… - Hepatology …, 2016 - Springer
Abstract The Asian-Pacific Association for the Study of the Liver (APASL) convened an
international working party on the “APASL consensus statements and recommendation on …
international working party on the “APASL consensus statements and recommendation on …
Current therapy for chronic hepatitis C: The role of direct-acting antivirals
G Li, E De Clercq - Antiviral research, 2017 - Elsevier
One of the most exciting developments in antiviral research has been the discovery of the
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
SL Friedman, V Ratziu, SA Harrison, MF Abdelmalek… - Hepatology, 2018 - journals.lww.com
Emerging studies have suggested that the Hippo pathway is involved in the tumorigenesis of
hepatocellular carcinoma (HCC). However, the key regulator of the Hippo pathway in liver …
hepatocellular carcinoma (HCC). However, the key regulator of the Hippo pathway in liver …
EASL recommendations on treatment of hepatitis C 2016
European Association for The Study of The Liver - Journal of hepatology, 2017 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
EASL clinical practice guidelines: liver transplantation
European Association for The Study of the Liver - Journal of hepatology, 2016 - Elsevier
The first human orthotopic liver transplantation (LT) in Europe was performed by Sir Roy
Calne in Cambridge in 1968 [1], only one year after the first successful human liver …
Calne in Cambridge in 1968 [1], only one year after the first successful human liver …
Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis
MP Curry, JG O'Leary, N Bzowej, AJ Muir… - … England Journal of …, 2015 - Mass Medical Soc
Background As the population that is infected with the hepatitis C virus (HCV) ages, the
number of patients with decompensated cirrhosis is expected to increase. Methods We …
number of patients with decompensated cirrhosis is expected to increase. Methods We …
[HTML][HTML] EASL recommendations on treatment of hepatitis C 2015
European Association For The Study Of The Liver - Journal of hepatology, 2015 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
[HTML][HTML] Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease
Background & Aims There are no effective and safe treatments for chronic hepatitis C virus
(HCV) infection of patients who have advanced liver disease. Methods In this phase 2, open …
(HCV) infection of patients who have advanced liver disease. Methods In this phase 2, open …
[HTML][HTML] The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation
The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV)
infection has resulted in a profound shift in the approach to the management of this infection …
infection has resulted in a profound shift in the approach to the management of this infection …
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised …
Background Treatment options are limited for patients infected by hepatitis C virus (HCV)
with advanced liver disease. We assessed the safety and efficacy of ledipasvir, sofosbuvir …
with advanced liver disease. We assessed the safety and efficacy of ledipasvir, sofosbuvir …